Halozyme Therapeutics Inc.

HALO | NASDAQ

Price Alert Chart Builder DCF Calculator

$130.91

-$0.27 (-0.21%)

At close: Oct 30, 2026, 4:00 PM ET

$130.91

$0.00 (0.00%)

Pre-market: Nov 2, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.21%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

78.6

Fundamentals Excellent

Market Sentiment Neutral

Moat Wide

Sector Rank #22/1028 (Top 2%)

Full Analysis

Key Statistics

Market Data

Market Cap $14.86B

1D Range

130.31 133.96

52W Range

61.63 133.96

Valuation (TTM)

PE 39.08

PB 103.51

EV/EBITDA 23.49

Valuation (NTM)

Forward PE 12.17

Forward PEG 1.18

Price Target $110.00

Cash Flow

FCF Yield 5.4%

SBC Adj. FCF Yield 5.0%

SBC Impact -7.8%

Margins

Gross Margin 82.4%

Operating Margin 56.8%

FCF Margin 48.5%

Growth (CAGR)

Revenue 3Y | 5Y 29.1% | 32.2%

Dil EPS 3Y | 5Y 25.1% | 16.5%

FCF 3Y | 5Y 40.2% | 40.1%

Returns

ROA 16.1%

ROE 180.6%

ROIC 27.0%

Financial Health

Net Debt

$1.92B

Current Ratio 2.71

Interest Coverage 45.84

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other internati...

Sector Healthcare

Industry Biotechnology

Employees 423

IPO Date Mar 16, 2004

Website www.halozyme.com

Fiscal Year January - December

Full Company Profile

Latest News

2 days ago · zacks.com

HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.

3 days ago · zacks.com

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago · businesswire.com

HALO-Flight Strengthens its Texas-based Air Med Fleet with Additional Bell 407GXi Purchase Order

FORT WORTH, Texas--(BUSINESS WIRE)--AMTC-- Bell Textron Inc., a Textron Inc. (NYSE: TXT) company, announced during the annual Air Medical Transport Conference (AMTC) 2026 the purchase order for a Bell 407GXi to HALO-Flight, further expanding the ability to deliver rapid, life-saving air medical transport to patients across South Texas. This aircraft marks the seventh IFR-equipped Bell 407GXi to soon join the HALO fleet, enhancing reliability and providing time-sensitive care across the region.

11 days ago · prnewswire.com

Halozyme to Report Third Quarter 2026 Financial and Operating Results

SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, following the close of trading. Halozyme will host a conference call on Thursday, November 5, 2026 at 1:30pm PT/4:30pm ET to discuss the results.

12 days ago · fxempire.com

Halozyme's Strong Earnings Growth Sends Shares Higher

Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.

19 days ago · zacks.com

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

19 days ago · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

20 days ago · zacks.com

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.